ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Nanosensitizer for Cancer Radioimmunotherapy via Anti-IL-35 Blockade Boosted Innate Immunity Activation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
- Nanosensitizer for Cancer Radioimmunotherapy via Anti-IL-35 Blockade Boosted Innate Immunity Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The cGAS-STING signaling pathway: emerging targets and challenges in breast cancer immunotherapy.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The cGAS-STING signaling pathway has emerged as a promising target for cancer immunotherapy. However, STING agonists have a dual-edged nature. Although they enhance antitumor T cell activity, STING agonists also elicit protumorigenic effects by promoting IL-35-producing B regulatory (Breg) cells, suppressing natural killer (NK) cell density, and fostering immune suppression. To address these challenges, this work develops a tumor microenvironment-responsive hollow mesoporous nanosystem that degrades under high glutathione conditions, thereby releasing the STING agonist MSA-2 and Mn ions. This nanosystem facilitates magnetic resonance imaging-guided chemodynamic therapy and radiosensitization, efficiently activating the cGAS-STING pathway by disrupting mitochondrial and nuclear DNA. Notably, by integrating this nanosystem with an anti-IL-35 blockade, this work successfully mitigates the Breg cell-mediated suppression of NK cells, restores innate immune responses, and enhances antitumor efficacy. This study highlights the pivotal role of anti-IL-35 in reversing immunosuppression, enhancing innate immunity, and establishing a synergistic theranostic platform for molecular imaging-guided cancer radioimmunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.